Epidermal growth factor receptor (EGFR) inhibitors are mainly used for the targeted therapy of non-small cell lung cancer (NSCLC).Therefore, EGFR mutations should be detected to treat lung cancer.The aim of this study is to determine the detection rate of NSCLC in patients with EGFR gene mutations by conducting direct sequencing and ARMS assay. This evidence concerns the gene EGFR and non-small cell lung carcinoma.